All In Biotech

Free tool

FAERS Monitor: Ycanth

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212905 or its brand name (Ycanth, Cantharidin). Reports on generic versions are filed under their own applications.

Reports

183

Serious

33

18% of reports

Hospitalization

9

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • application site vesicles78
  • application site pain53
  • blister30
  • pain16
  • application site burn12
  • blister rupture8
  • hypersensitivity8
  • application site erythema7
  • drug ineffective7
  • accidental exposure to product6
  • chemical burn6
  • wrong technique in product usage process6
  • blood blister5
  • product use issue5
  • pyrexia5

Reports by year received

View as table
YearReports
20111
20121
20151
20161
20195
20211
20221
20239
202458
202559
202646

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,976 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site vesiclesSignal781399.11180.5106,320
blister ruptureSignal81253.9634.38,707
chemical burnSignal6601.8273.43,008
application site burnSignal12280.7162.33,063
application site painSignal53277.2220.814,292
blood blisterSignal5184.277.5736
blisterSignal3061.444.31,727
application site erythemaSignal730.714.8173
accidental exposure to productSignal66.73.024
hypersensitivitySignal85.02.522
wrong technique in product usage processSignal63.41.58
product use issueSignal53.11.35
painSignal163.01.920
pyrexia51.70.71
drug ineffective70.60.31

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.